Trial Profile
Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fispemifene (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- 15 Jan 2007 Status change
- 14 Oct 2006 Status change
- 06 Mar 2006 New trial record.